Neuropathy Assessment and Treatment Patterns in Patients With Hereditary Transthyretin Amyloidosis: A Single-Center Analysis of Stabilizer and Gene Silencer Utilization

Nicholas Streicher, MD[1]; Hermela Wubet[2]

[1] Department of Neurology, Georgetown University, Washington, DC

[2] MedStar Health Research Institute, Washington, DC

ABSTRACT

Background: Hereditary transthyretin amyloidosis (hATTR) manifests as cardiomyopathy and/or polyneuropathy. The V142I variant predominantly causes cardiac disease in African Americans, though neurological involvement may be underrecognized. We characterized neuropathy documentation and treatment patterns in a predominantly V142I cohort.

Methods: Retrospective review of 54 hATTR patients identified by ICD-10 coding for amyloidosis and neuropathy at a major academic medical center, with pathogenic TTR variant confirmation. Neuropathy was classified as: neuropathy with ancillary testing, neuropathy without ancillary testing, symptoms only, or unclear. Treatment with stabilizers (tafamidis, acoramidis, diflunisal) and gene silencers (patisiran, vutrisiran, eplontersen) was assessed.

Results: Of 54 patients (88.9% African American, 85.2% V142I), 51 (94.4%) had confirmed cardiac involvement. Among cardiac patients, 40/42 eligible (95.2%) received stabilizers. Overall, 16 patients (29.6%) received gene silencers, with 13 (24.1%) receiving both a stabilizer and gene silencer concurrently. Confirmed or suspected neuropathy (with ancillary testing, without ancillary testing, or symptoms only) was present in 30 patients (55.6%). Gene silencer use was highest among those with ancillary testing confirmation (8/17, 47.1%) versus symptoms only (1/10, 10.0%). All three patients without confirmed cardiac disease received gene silencers.

Conclusions: In this V142I-predominant cohort with 94.4% cardiac involvement, stabilizer use was high (95.2%) among eligible patients. Over half had confirmed or suspected neuropathy based on clinical documentation, though EMG completion was limited (57.4%). Gene silencer use was associated with ancillary testing confirmation of neuropathy and non-cardiac phenotype. These findings support systematic neurological assessment in hATTR, even when cardiac disease predominates.

INTRODUCTION

Hereditary transthyretin amyloidosis (hATTR) is an autosomal dominant systemic disease caused by mutations in the transthyretin (TTR) gene that lead to misfolding and tissue deposition of amyloid fibrils.[1,13] Clinical manifestations primarily affect the heart and peripheral nervous system, with phenotypic expression varying by specific genetic variant, geographic ancestry, and individual factors.[2,13]

The V142I variant is the most common pathogenic TTR mutation worldwide, carried by approximately 3–4% of African Americans—representing an estimated 1.2 to 1.5 million individuals in the United States.[2,3] This variant classically produces a cardiac-predominant phenotype with heart failure symptoms typically manifesting after age 60, leading to its historical characterization as a cardiomyopathy.[2] However, emerging evidence suggests neurological involvement may be more prevalent than previously recognized, with large database studies demonstrating significantly elevated polyneuropathy diagnoses among V142I carriers compared to non-carriers.[4,5]

The therapeutic landscape for hATTR has expanded substantially. TTR stabilizers (tafamidis, acoramidis, diflunisal) prevent tetramer dissociation, with tafamidis demonstrating mortality benefit in ATTR cardiomyopathy[6] and evidence supporting neurological benefit in patients with mixed phenotypes.[7,8] Gene silencer therapies (patisiran, vutrisiran, eplontersen) reduce hepatic TTR synthesis through RNA interference or antisense mechanisms, with established efficacy for polyneuropathy[9,10,11] and emerging data supporting cardiac benefits.[12] Understanding treatment utilization patterns—particularly for gene silencers that may address both cardiac and neurological manifestations—has important implications as therapeutic indications evolve.

We conducted a retrospective analysis of hATTR patients at a major academic medical center to characterize neuropathy assessment patterns and examine the relationship between neurological findings and treatment selection, with particular focus on gene silencer utilization in this predominantly V142I population.

METHODS

Study Design and Population

We performed a retrospective cohort study of patients diagnosed with hATTR at a major academic medical center. Patients were identified through institutional electronic medical record query of encounters over approximately eight years (2017–2025), using ICD-10 coding for amyloidosis and neuropathy diagnoses, with confirmation of a pathogenic TTR variant through genetic testing documentation. All cases were individually reviewed to verify clinical status. No patients in our cohort were prescribed gene silencers under the ATTR cardiomyopathy indication; all gene silencer use reflected the polyneuropathy indication. We excluded patients with unknown genotype, those receiving hospice or comfort care only, and pre-symptomatic carriers identified through family screening who had not developed clinical manifestations.

Data Collection

Electronic medical records were reviewed for demographic information, TTR variant, cardiac involvement documentation (echocardiography, cardiac MRI, technetium pyrophosphate scintigraphy), neurological assessments (neurology consultations, electromyography/nerve conduction studies), and treatments received.

Neuropathy Classification

Patients were classified into four mutually exclusive categories based on highest level of neuropathy documentation:

> *Neuropathy with ancillary testing*: abnormal EMG/nerve conduction study consistent with polyneuropathy.
>
> *Neuropathy without ancillary testing*: clinical documentation of neuropathy by a provider without confirmatory ancillary testing.
>
> *Symptoms only*: patient-reported neuropathic symptoms (numbness, tingling, pain) documented in medical records without clinical examination findings or formal neurological evaluation.
>
> *Unclear*: insufficient documentation to assess neurological status.

"Confirmed or suspected neuropathy" was defined as the combined group of patients with neuropathy with ancillary testing, neuropathy without ancillary testing, or symptoms only—representing all patients with any clinical evidence suggesting neurological involvement.

Treatment Assessment

Current or prior treatment was assessed for TTR stabilizers (tafamidis, acoramidis, diflunisal) and gene silencers (patisiran, vutrisiran, eplontersen). Stabilizer eligibility for cardiac patients was defined as confirmed ATTR cardiomyopathy without documented contraindication or patient refusal.

Confounding Conditions

We documented conditions that may cause or contribute to neuropathy independent of amyloidosis: diabetes mellitus, chronic kidney disease (eGFR <60), alcohol use disorder, and vitamin B12 deficiency. These confounders were assessed to contextualize neuropathy findings and treatment decisions.

RESULTS

Patient Characteristics

Fifty-four patients met inclusion criteria (Table 1). The cohort was predominantly African American (48/54, 88.9%) with V142I as the most common variant (46/54, 85.2%). Other variants included V50M (3 patients), A140S (2 patients), T60A, V132I, and P84L (1 patient each). Median age at diagnosis was 72 years (range 51–89).

Table 1. Patient Demographics and Clinical Characteristics (N=54)

Characteristic	n	%

Race		
African American	48	88.9
White	5	9.3
Unknown	1	1.9
TTR Variant		
V142I	46	85.2
V50M	3	5.6
A140S	2	3.7
Other (T60A, V132I, P84L)	3	5.6
Cardiac Status		
Confirmed cardiac involvement	51	94.4
No confirmed cardiac involvement	3	5.6
Treatment		
Stabilizer	40	74.1
Gene silencer	16	29.6
Both stabilizer + gene silencer	13	24.1

[a] Values may not add to 100 because of rounding.

Confirmed cardiac involvement was present in 51 patients (94.4%), consistent with the expected cardiac-predominant phenotype of V142I.[2] Among patients with confirmed cardiomyopathy who were eligible for stabilizer therapy, 40 of 42 (95.2%) were receiving treatment. Thirteen patients (24.1%) were receiving both a stabilizer and a gene silencer concurrently, with gene silencers added to stabilizer therapy rather than replacing it. Nine cardiac patients were not receiving stabilizers: eight had documented negative cardiac workup despite ICD-10 coding, and two lacked documented clinical reasoning for non-treatment.

Neuropathy Classification

Neuropathy classification and treatment patterns are shown in Table 2. Neuropathy confirmed by ancillary testing (abnormal EMG in this cohort) was documented in 17 patients (31.5%), neuropathy without ancillary testing in 13 (24.1%), and symptoms only in 10 (18.5%). Fourteen patients (25.9%) had unclear neurological status. Overall, 30 patients (55.6%) had confirmed or suspected neuropathy based on available documentation.

Table 2. Neuropathy Classification and Treatment Patterns (N=54)

Classification	n	%	Stabilizer	%	Silencer	%
With ancillary testing	17	31.5	14	82.4	8	47.1
Without ancillary	13	24.1	11	84.6	4	30.8

testing						
Symptoms only	10	18.5	7	70.0	1	10.0
Unclear	14	25.9	8	57.1	3	21.4

Confounding Conditions

Table 2a shows treatment patterns stratified by presence of confounding conditions. Among the 16 patients without confounders, 13 (81.2%) received stabilizers and 5 (31.2%) received gene silencers. Among 38 patients with one or more confounders, 27 (71.1%) received stabilizers and 11 (28.9%) received gene silencers.

Table 2a. Treatment by Presence of Confounding Conditions (N=54)

Confounder Status	n	Stabilizer (%)	Silencer (%)	Confounders
No confounders	16	13 (81.2)	5 (31.2)	—
With confounders	38	27 (71.1)	11 (28.9)	DM, CKD, EtOH, B12

DM = diabetes mellitus; CKD = chronic kidney disease; EtOH = alcohol use disorder; B12 = vitamin B12 deficiency

Analysis by Cardiac Status

Table 3 presents neurological assessment and treatment stratified by cardiac status. Among 51 patients with cardiac involvement, 29 (56.9%) had confirmed or suspected neuropathy. Neurology consultation rates were higher among those with confirmed or suspected neuropathy (28/29, 96.6%) compared to unclear status (15/22, 68.2%). EMG completion was 75.9% among those with confirmed or suspected neuropathy versus 40.9% in the unclear group.

Three patients lacked confirmed cardiac involvement. One had V142I with ancillary testing confirmation of neuropathy and was receiving vutrisiran. Two had unclear neurological status: one V50M patient on eplontersen and one P84L patient on patisiran. All three (3/3, 100%) received gene silencers rather than stabilizers, consistent with their non-cardiac phenotype.

Table 3. Neurological Assessment and Treatment by Cardiac Status

Cardiac	Neuro	n	Consult	%	EMG	%	Silencer	%	Stab
Yes (n=51)	Confirmed/Suspected	29	28	96.6	22	75.9	11	37.9	25
	Unclear	22	15	68.2	9	40.9	2	9.1	15
No (n=3)	Confirmed/Suspected	1	1	100	1	100	1	100	0
	Unclear	2	2	100	2	100	2	100	0

DISCUSSION

V142I Phenotype and Neurological Involvement

This single-center analysis of 54 hATTR patients—predominantly V142I carriers of African ancestry—confirms the expected cardiac-predominant phenotype while revealing substantial rates of confirmed or suspected neuropathy. The finding that 55.6% (30/54) had documented neuropathic symptoms or signs aligns with recent population-based studies demonstrating elevated polyneuropathy prevalence among V142I carriers,[4] challenging the traditional characterization of this variant as exclusively cardiac.[5] Notably, reported neuropathy prevalence among V142I carriers varies widely across studies—from approximately 2–9% using administrative ICD-10 coding[4] to over 90% at specialized centers employing nerve conduction studies and skin biopsy[5]—highlighting that diagnostic methodology may be a primary driver of apparent variation in disease prevalence.

Our observation that three patients lacked confirmed cardiac involvement despite carrying pathogenic TTR variants (one V142I, one V50M, one P84L) is noteworthy. These patients may represent early detection through cascade screening or genuinely neurologic-predominant phenotypes. As genetic testing expands, identifying gene-positive individuals before cardiac manifestations develop will become more common.

Treatment Patterns

Stabilizer utilization among eligible cardiac patients was high (95.2%), reflecting established practice following pivotal trial data demonstrating mortality benefit.[6] Gene silencer use showed a clear gradient by neuropathy documentation: highest in patients with ancillary testing confirmation (47.1%), intermediate with neuropathy documented without ancillary testing (30.8%), and lowest with symptoms only (10.0%). Notably, 13 of 16 patients receiving gene silencers were also on concurrent stabilizer therapy, reflecting an additive prescribing pattern in which gene silencers were layered onto existing stabilizer treatment rather than substituted for it.

The three patients without confirmed cardiac disease received gene silencers rather than stabilizers, consistent with their neurologic-predominant phenotype. No patients in our cohort were prescribed gene silencers under the recently approved ATTR cardiomyopathy indication (FDA March 2025, based on HELIOS-B trial data[12]); all gene silencer access was predicated on neurological documentation.

With vutrisiran now approved for cardiomyopathy, cardiologists can prescribe gene silencers based on the cardiac indication alone—potentially without formal neurological consultation. This shifts the treatment pathway in important ways. Patients may appropriately receive gene silencers for cardiac benefit, but the neuropathy component may go uncharacterized—not because it is absent, but because its documentation is no longer required for treatment access. Cardiologists may reasonably assume neurological involvement is present, or may not pursue the question at all, since the prescribing decision no longer depends on it.

Our finding that over half of patients in a cardiac-predominant cohort had documented neuropathy suggests that systematic neurological assessment adds clinical value beyond treatment access—including establishing baseline neuropathy severity, guiding monitoring, and identifying patients who may benefit from multidisciplinary management.

Limitations

This retrospective single-center analysis relies on available documentation. No patients in our cohort were prescribed gene silencers under the ATTR cardiomyopathy indication (FDA approved March 2025); all gene silencer use reflects the polyneuropathy indication, and current prescribing patterns may differ as adoption of the expanded indication increases.

Our V142I-predominant cohort limits generalizability to other variants. The small number of patients without cardiac involvement (n=3) limits statistical inference for that subgroup—these patients may represent early detection through cascade screening or genuinely neurologic-predominant phenotypes, a pattern likely to become more common as genetic testing expands.

ICD-10 codes are an inherent limitation of retrospective cohort identification—codes may overcapture patients without confirmed disease or undercapture those whose conditions are not coded. All cases were individually reviewed, leading to the exclusion of four identified carriers, though additional unrecognized carriers may remain. Not all patients had endomyocardial biopsy confirmation of cardiac amyloid deposition; cardiac involvement was determined through imaging modalities including technetium pyrophosphate scintigraphy, echocardiography, and cardiac MRI. Ancillary neuropathy testing in our cohort was limited to conventional EMG/nerve conduction studies; skin biopsy for intraepidermal nerve fiber density and autonomic testing were not performed as part of routine clinical practice, though such modalities may identify neuropathic involvement not captured by conventional electrodiagnostic studies. This likely contributes to the difference between the 31.5% rate observed with EMG in our cohort and the 90% prevalence reported in studies employing skin biopsy and standardized neurologic examination.[5]

We assessed common confounding conditions, but neuropathy has numerous potential etiologies—attribution of neuropathy specifically to amyloid deposition versus other causes cannot be definitively established from chart review alone. We could not assess clinical reasoning behind individual treatment decisions, including patient preferences and insurance barriers.

Future Directions

Serum biomarkers such as neurofilament light chain (NfL) may help identify patients with active neurological involvement and guide treatment selection. Preliminary observations suggest these markers may be selectively elevated in patients with neuropathic phenotypes. Nerve ultrasound represents a promising non-invasive alternative to sural nerve biopsy for detecting structural nerve abnormalities.

Additionally, patient-reported outcomes through structured interviews would provide important perspectives on the diagnostic journey—including time from symptom onset to diagnosis, barriers to specialty referral, and treatment awareness—not captured in chart review.

The wide variation in reported neuropathy prevalence among V142I carriers—ranging from approximately 2–9% in population-based studies[4] to over 90% at specialized centers[5]—likely reflects differences in diagnostic methodology rather than true differences in disease biology. Published studies have applied a range of approaches to define neuropathy, from administrative ICD-10 coding to conventional nerve conduction studies to intraepidermal nerve fiber density on skin biopsy, each with different sensitivity for detecting neuropathic involvement.

Our own data illustrate this: the apparent neuropathy rate in our cohort ranges from 31.5% when restricted to objective EMG confirmation to 55.6% when clinical documentation of symptoms is included. Standardizing neuropathy assessment criteria in hATTR—including which diagnostic modalities to employ and how to account for competing etiologies in this patient population—represents an important area for future investigation.

CONCLUSIONS

In this predominantly V142I cohort, 94.4% had confirmed cardiac involvement, consistent with the known cardiac-predominant phenotype. Stabilizer use was high (95.2%) among eligible cardiac patients. Over half (55.6%) had confirmed or suspected neuropathy based on clinical documentation, though EMG completion remained limited. Gene silencer utilization was highest among patients with ancillary testing confirmation of neuropathy and those without cardiac involvement. These findings support systematic neurological assessment in hATTR, even when cardiac disease predominates, and suggest gene silencer therapy may be underutilized in patients with documented neuropathy. The method by which neuropathy is diagnosed—whether through administrative coding, clinical documentation, or formal neurophysiologic testing—substantially influences apparent prevalence and warrants standardization.

ACKNOWLEDGEMENTS

We thank Lori Biddle for editorial assistance with this manuscript.

REFERENCES

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. *N Engl J Med*. 2003;349(6):583-596. doi:10.1056/NEJMra023144
2. Buxbaum JN, Ruberg FL. Transthyretin V122I cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy. *Genet Med*. 2017;19(7):733-742. doi:10.1038/gim.2016.200
3. Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14,333 African-Americans. *Amyloid*. 2015;22(3):171-174. doi:10.3109/13506129.2015.1051219
4. Parker MM, Damrauer SM, Tcheandjieu C, et al. Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry. *Sci Rep*. 2021;11(1):11645. doi:10.1038/s41598-021-91113-6
5. Zampino S, Sheikh FH, Vaishnav J, et al. Phenotypes associated with the Val122Ile, Leu58His, and late-onset Val30Met variants in patients with hereditary transthyretin amyloidosis. *Neurology*. 2023;100(19):e2036-e2044. doi:10.1212/WNL.0000000000207158
6. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. *N Engl J Med*. 2018;379(11):1007-1016. doi:10.1056/NEJMoa1805689
7. Waddington Cruz M, Amass L, Keohane D, et al. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. *Amyloid*. 2016;23(3):178-183. doi:10.1080/13506129.2016.1207163
8. Streicher N, Amass L, Wang R, et al. Real-world effectiveness of high-dose tafamidis on neurologic disease progression in mixed-phenotype variant transthyretin amyloid cardiomyopathy. *Cardiol Ther*. 2024;13(2):359-368. doi:10.1007/s40119-024-00362-9
9. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. *N Engl J Med*. 2018;379(1):11-21. doi:10.1056/NEJMoa1716153
10. Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. *Amyloid*. 2023;30(1):18-26. doi:10.1080/13506129.2022.2091985
11. Coelho T, Marques W Jr, Dasgupta NR, et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. *JAMA*. 2023;330(15):1448-1458. doi:10.1001/jama.2023.18688
12. Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. *N Engl J Med*. 2025;392(1):33-44. doi:10.1056/NEJMoa2409134
13. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. *J Am Coll Cardiol*. 2019;73(22):2872-2891. doi:10.1016/j.jacc.2019.04.003